Literature DB >> 19925605

A prospective randomized multicenter comparison on health-related quality of life: the value of add-on arrhythmia surgery in patients with paroxysmal, permanent or persistent atrial fibrillation undergoing valvular and/or coronary bypass surgery.

H N A M Van Breugel1, F H M Nieman, R E Accord, G A P G Van Mastrigt, J F M A Nijs, J L Severens, R Vrakking, J G Maessen.   

Abstract

INTRODUCTION: This is a multicenter, prospective, randomized controlled trial to determine the effect of add-on arrhythmia surgery on health-related quality of life during 1-year follow-up of cardiac surgery patients with atrial fibrillation.
METHODS: 150 patients with documented atrial fibrillation were randomly assigned to undergo cardiac surgery with or without add-on surgery. Patients completed quality of life questionnaires, comprising the RAND 36-item Health Survey 1.0 (SF-36), Multidimensional Fatigue Inventory-20 (MFI-20) and EuroQoL (EQ-5D and VAS) at baseline and 3, 6, and 12 months following operation.
RESULTS: 132 patients completed the questionnaires at a minimum of one time-point during follow-up. At baseline patient characteristics, operative data and health-related quality of life were comparable. At 12-month follow-up 62 patients were free of atrial fibrillation without significant differences between groups (P = 0.28). Conversion to SR occurred in 69.8% (37/53) of patients with paroxysmal AF, in 28.2% (11/39) of patients with permanent AF and in 44.4% (12/27) of patients in persistent AF. Cardiac surgery in general resulted in an overall improvement of the RAND SF-36 and the MFI-20. However, the EQ-5D showed a significant deterioration in the subscale Pain/Discomfort for both groups (P < 0.001), with a significant worse outcome for the control group (P = 0.006).
CONCLUSIONS: Health-related quality of life in patients with paroxysmal, permanent and persistent atrial fibrillation improves after cardiac surgery regardless of giving add-on surgery or not, but this improvement is presumably more affected by treating the underlying heart disease than by restoring sinus rhythm.

Entities:  

Mesh:

Year:  2009        PMID: 19925605     DOI: 10.1111/j.1540-8167.2009.01655.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  5 in total

1.  Guideline adherence in antithrombotic treatment after concomitant ablation surgery in atrial fibrillation patients.

Authors:  Henrica N A M van Breugel; Sandro Gelsomino; Pieter W J Lozekoot; Ryan E Accord; Fabiana Lucà; Orlando Parise; Harry J G M Crijns; Jos G Maessen
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-12-13

Review 2.  Concomitant atrial fibrillation surgery for people undergoing cardiac surgery.

Authors:  Mark D Huffman; Kunal N Karmali; Mark A Berendsen; Adin-Cristian Andrei; Jane Kruse; Patrick M McCarthy; S C Malaisrie
Journal:  Cochrane Database Syst Rev       Date:  2016-08-22

3.  Amaze: a randomized controlled trial of adjunct surgery for atrial fibrillation.

Authors:  Samer A M Nashef; Simon Fynn; Yasir Abu-Omar; Tomasz J Spyt; Christine Mills; Colin C Everett; Julia Fox-Rushby; Jeshika Singh; Malcolm Dalrymple-Hay; Catherine Sudarshan; Massimiliano Codispoti; Peter Braidley; Francis C Wells; Linda D Sharples
Journal:  Eur J Cardiothorac Surg       Date:  2018-10-01       Impact factor: 4.191

4.  Patient-reported quality of life after stand-alone and concomitant arrhythmia surgery: a systematic review and meta-analysis.

Authors:  Bart Maesen; Claudia A J van der Heijden; Elham Bidar; Rein Vos; Thanos Athanasiou; Jos G Maessen
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-02-21

5.  Does sinus rhythm conversion after cardiac surgery affect postoperative health- related quality of life?

Authors:  Henrica N A M van Breugel; Orlando Parise; Fred H M Nieman; Ryan E Accord; Fabiana Lucà; Pieter Lozekoot; Narendra Kumar; Ghislaine A P G van Mastrigt; Jan F M A Nijs; Ries Vrakking; Jos G Maessen; Mark La Meir; Sandro Gelsomino
Journal:  J Cardiothorac Surg       Date:  2016-05-03       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.